Cargando…

Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence

Injectable extended-release naltrexone (XRNTX) presents an effective therapeutic strategy for opioid addiction, however its utility could be hampered by poor adherence. To gain a better insight into this phenomenon, we utilized blood oxygenation level-dependent functional magnetic resonance imaging...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, A-L, Elman, I, Lowen, S B, Blady, S J, Lynch, K G, Hyatt, J M, O'Brien, C P, Langleben, D D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354350/ https://www.ncbi.nlm.nih.gov/pubmed/25781230 http://dx.doi.org/10.1038/tp.2015.20

Ejemplares similares

Association between body mass index and treatment completion in extended-release naltrexone-treated patients with opioid dependence
por: Li, Xinyi, et al.
Publicado: (2023)

Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients
por: Zaaijer, Eline R., et al.
Publicado: (2015)

Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia
por: Ruger, Jennifer Prah, et al.
Publicado: (2012)

Naltrexone as a Treatment for Heroin Dependence and its relationship with Depression
por: Kak, Insha Mehraj, et al.
Publicado: (2022)

Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder
por: Shi, Zhenhao, et al.
Publicado: (2019)

Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
por: Velasquez, Melissa, et al.
Publicado: (2019)

Naltrexone extended-release injection: an option for the management of opioid abuse
por: Taylor, Robert, et al.
Publicado: (2011)

Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
por: Nunes, Edward V., et al.
Publicado: (2015)

Factors associated with willingness to take extended release naltrexone among injection drug users
por: Ahamad, Keith, et al.
Publicado: (2015)

Patients’ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study
por: Marciuch, Anne, et al.
Publicado: (2022)

Naltrexone/Bupropion extended release‐induced weight loss is independent of nausea in subjects without diabetes
por: Hong, K., et al.
Publicado: (2016)

The Vivitrol pilot program (VPP): initial quantitative findings from an extended-release naltrexone study
por: Rieckmann, Traci, et al.
Publicado: (2015)

Medication Treatment for Opioid Use Disorders:: A Brief Overview with Comments on Extended Release Naltrexone
por: Woody, George
Publicado: (2017)

Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone
por: Marciuch, Anne, et al.
Publicado: (2023)

Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
por: Earley, Paul H., et al.
Publicado: (2017)

Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic
por: Nguyen, Thuy, et al.
Publicado: (2022)

The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV
por: Parchinski, Kaley, et al.
Publicado: (2023)

Epidemiologic and Molecular Pathophysiology of Chronic Opioid Dependence and the Place of Naltrexone Extended-Release Formulations in its Clinical Management
por: Reece, Albert Stuart
Publicado: (2012)

Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018
por: Jain, Priya, et al.
Publicado: (2020)

Adaptation of a standard extended-release naltrexone (XR-NTX) protocol for rural re-entering offenders with OUD
por: Staton, Michele, et al.
Publicado: (2021)

Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone
por: Karlsson, Ann Tarja, et al.
Publicado: (2022)

Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations
por: Cook, R. R., et al.
Publicado: (2023)

Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis
por: Hoffman, Kim A., et al.
Publicado: (2021)

Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder
por: Perez-Macia, Virginia, et al.
Publicado: (2021)

Buprenorphine is a weak dopamine releaser relative to heroin, but its pretreatment attenuates heroin‐evoked dopamine release in rats
por: Isaacs, Dominic P., et al.
Publicado: (2020)

Whose mu fared better? The effect of extended-release naltrexone (XR-NTX) on treatment outcomes for opioid and alcohol users
por: Crèvecoeur-MacPhail, Desirée A
Publicado: (2015)

The Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the Literature
por: Ramsey, Susan E., et al.
Publicado: (2016)

Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR
Publicado: (2012)

Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials
por: Murphy, Sean M., et al.
Publicado: (2020)

Liposomal extended-release bupivacaine for postsurgical analgesia
por: Lambrechts, Mark, et al.
Publicado: (2013)

Low Message Sensation Health Promotion Videos Are Better Remembered and Activate Areas of the Brain Associated with Memory Encoding
por: Seelig, David, et al.
Publicado: (2014)

Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens
por: Comer, Sandra D., et al.
Publicado: (2020)

Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
por: Caixàs, Assumpta, et al.
Publicado: (2014)

Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics
por: Coplan, Paul M, et al.
Publicado: (2013)

Neural Correlates of Drug-Related Attentional Bias in Heroin Dependence
por: Zhao, Qinglin, et al.
Publicado: (2018)

Heroin Inhalation Leukoencephalopathy: An Overlooked Entity in the Opioid Epidemic
por: Farrell, Aidan, et al.
Publicado: (2023)

Pharmacokinetic Correlates of the Effects of a Heroin Vaccine on Heroin Self-Administration in Rats
por: Raleigh, Michael D., et al.
Publicado: (2014)

Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
por: Kunøe, Nikolaj, et al.
Publicado: (2016)

Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product
por: Pergolizzi, Joseph V, et al.
Publicado: (2018)

Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended‐release naltrexone in a residential setting
por: Mannelli, Paolo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cflr3kb00o51uio00v4l5njddt